Testing for EGFR mutations in the advanced NSCLC setting came into standard practice as early as 2011, when clinical trials were examining the place in therapy of the first-generation EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib (7). This evidence concerns the gene EGFR and non-small cell lung carcinoma.